Churchill Capital Corp X (NASDAQ:CCCX) shares are trading higher Thursday after Infleqtion announced a partnership with ...
Metasurfaces are two-dimensional (2D), nanoengineered surfaces that interact strongly with electromagnetic waves and can ...
A team from the Faculty of Physics and the Center for Quantum Optical Technologies at the University of Warsaw has developed ...
The SHARON trial is ongoing and will be expanding to include patients without a BRCA or PALB2 mutation, and General Oncology plans to continue evaluating outcomes and long-term follow-up in this ...
Glovadalen, a novel D1 receptor positive allosteric modulator, is linked to improve OFF time in patients with Parkinson’s ...
Arvinas has announced positive biomarker, pharmacokinetic and pharmacodynamic data from two Phase I studies assessing ARV-102 ...
NMIMS to roll out AI-led interviews with sentiment tracking, measuring facial expressions, tone, and confidence of MBA ...
Sanofi’s Wayrilz recommended for EU approval by the CHMP to treat immune thrombocytopeniaRecommendation based on LUNA 3 phase 3 study ...
Most recurrent ovarian cancer cases arise in patients previously treated with PARP inhibitors making these results noteworthy ...
ARV-102 was well tolerated in clinical trials for both healthy volunteers and patients with Parkinson’s disease – – ARV-102 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback